The Journal of Pathology / Volume 192, Issue 2 / p. 229-233

Original Paper

Errors in histological grading by prostatic needle biopsy specimens: frequency and predisposing factors

Emiel Ruijter, Geert van Leenders, Gary Miller, Frans Debruyne, Christina van de Kaa

First published: 16 August 2000 https://doi.org/10.1002/1096-9896(2000)9999:9999<::AID-PATH703>3.0.CO;2-X Citations: 35

Abstract

Sampling error is an inherent problem of prostate biopsy. Consequently, there are problems in determining whether a given carcinoma is clinically significant on the basis of biopsy results. This study assesses the factors that predispose to errors in biopsy grading, as well as the dimensions of sampling error due to these factors. Among 187 cases, biopsy grading error was retrospectively related to grade heterogeneity in the prostate and to biopsy-related factors. Clinically relevant biopsy grading errors occurred in a quarter of the cases. Of all grading errors, at least 17% resulted from misinterpretation by the pathologist only. Overall, prostates with grade heterogeneity revealed grading errors twice as frequently as specimens without grade heterogeneity. In most cases, however, grading error resulted from multiple factors, such as the number and length of cores obtained (p<0.05). This was an important finding because the mean core length was only 9.4 mm, whereas the biopsy needle is designed to obtain cores of 15 mm. Moreover, clinically relevant biopsy grading error had occurred in almost half of the cases when the Gleason score was based on a tumour deposit measvring less than 0.5 mm (p<0.05). The clinical consequences of these findings are important. Clinicians should try to obtain at least six biopsies, each 15 mm in length, to minimize grading error. Pathologists should be cautious in reporting Gleason scores based on tumour lesions smaller than 400x total magnification field. Interpretation could be refined, when

necessary, by warning the urologist of the Limitations of the biopsy report. Copyright © 2000 John Wiley & Sons, Ltd.

References

1 Iczkowski KA, MacLennan GT, Bostwick DG. Atypical small acinar proliferation of the prostate suspicious for malignancy in needle biopsies: Histologic features and clinical significance in 33 cases. *Am J Surg Pathol* 1997; **21**: 1489–1495.

2 Gleason DF. Histologic grading and clinical staging of prostate carcinoma. In *Urologic Pathology: the Prostate*. M Tannenbaum (ed.). Lea & Febiger: Philadelphia, PA,1977; 171–198.

3 Wills ML, Sauvageot J, Partin AW, Gurganus R, Epstein JI. Ability of sextant biopsies to predict radical prostatectomy stage. *Urology* 1998; **51**: 759–764.

4 Mills SE, Fowler JE. Gleason histologic grading of prostatic carcinoma. Correlations between biopsy and prostatectomy specimens. *Cancer* 1986; **57**: 346–349.

5 Bostwick DG. Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies. *Am J Surg Pathol* 1994; **18**: 796–803.

6 Garnett JE, Oyasu R, Grayhack JT. The accuracy of diagnostic biopsy specimens in predicting tumor grades by Gleason's classification of radical prostatectomy specimens. *J Urol* 1984; **131**: 690–693.

7 Spires SE, Cibull ML, Wood DP, Miller S, Spires SM, Banks ER. Gleason histologic grading in prostatic carcinoma. *Arch Pathol Lab Med* 1994; **118**: 705–708.

8 Ruijter TEG, van de Kaa CA, Schalken JA, Debruyne FMJ, Ruiter DJ. Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. *J Pathol* 1996; **180**: 295–299.

9 Hodge KK, McNeal JE, Terris MD, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. *J Urol* 1989; **142**: 71–75.

10 Gleason DF. Histologic grading of prostate cancer: a perspective. *Hum Pathol* 1992; 23: 273–279.

11 Bain G, Koch M, Hanson J. Feasibility of grading prostatic carcinomas. *Arch Pathol Lab Med* 1982; **106**: 265–267.

12 Ruijter ET, Werahera PN, van de Kaa CA, Stewart JS, Schalken JA, Miller GJ. Detection of abnormal E-cadherin expression by simulated prostate biopsy. *J Urol* 1998; **160**: 1368–1371.

Citing Literature

Download PDF

Pathological Society Understanding Disease — Guiding Therapy

Registered Charity in England and Wales: 1154851 Scottish Charity No SC045004 | Limited Company Registered in England and Wales: 8759028 Copyright © 2023 | Pathological Society

About Wiley Online Library

Privacy Policy Terms of Use About Cookies Manage Cookies Accessibility Wiley Research DE&I Statement and Publishing Policies Help & Support

> Contact Us Training and Support DMCA & Reporting Piracy

> > Opportunities

Subscription Agents Advertisers & Corporate Partners

Connect with Wiley

The Wiley Network Wiley Press Room

Copyright © 1999-2023 John Wiley & Sons, Inc. All rights reserved